Company news

Paradigm Biopharmaceuticals Ltd. news in 2025

Paradigm Biopharmaceuticals Ltd.'s news releases, calls and decks from 2025, newest first.

View company

Phase 3 Knee OA Trial Recruitment Update

December 22, 2025

Drawdown of Tranche 2 under the Convertible Note Facility

November 17, 2025

September 2025 Quarterly Activities Report & Appendix 4C

October 29, 2025

Phase 3 Knee OA Trial Recruiting and Dosing in AUS & US

September 30, 2025

Appendix 4E and 2025 Annual Report

August 29, 2025

June 2025 Quarterly Activities Report & Appendix 4C

July 28, 2025

Paradigm Secures US$27M to Advance Phase 3 OA Trial

June 30, 2025

Paradigm Strengthens OA Pipeline with Strategic Acquisition

June 25, 2025

PAR Receives US Ethics Approval for Phase 3

May 14, 2025

March 2025 Quarterly Activities Report & Appendix 4C

April 29, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Paradigm Secures Ethics Approval for Phase 3 Trial

February 23, 2025

Loyalty and Piggyback Options Program

January 31, 2025

PAR Selects Advanced Clinical as CRO for Phase 3

January 30, 2025

Quarterly Activities/Appendix 4C Cash Flow Report

January 30, 2025

Paradigm Receives $6.3m R&D Tax Refund

January 23, 2025

Decks in 2025